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Abstract 
Background: The number of injections in the dose escalation of subcutaneous immunotherapy (SCIT) is small for 
some currently used hypoallergenic allergoids, but can still be inconvenient to patients and can impair compliance. 
The aim of this trial was to compare safety and tolerability of an accelerated to the conventional dose escalation 
scheme of a grass pollen allergoid.
Methods: In an open label phase II trial, 122 patients were 1:1 randomized for SCIT using a grass pollen allergoid with 
an accelerated dose escalation comprising only 4 weekly injections (Group I) or a conventional dose escalation includ‑
ing 7 weekly injections (Group II). Safety determination included the occurrence of local and systemic adverse events. 
Tolerability was assessed by patients and physicians.
Results: Treatment‑related adverse events were observed in 22 (36.1 %) patients in Group I and 15 (24.6 %) in Group 
II. Local reactions were reported by 18 patients in Group I and 11 in Group II. Five Grade 1 systemic reactions (WAO 
classification) were observed in Group I and 2 in Group II. Grade 2 reactions occurred 3 times in Group I and 2 times 
in Group II. Tolerability was rated as “good” or “very good” by 53 (86.9 %) patients in Group I and 59 (100 %) in Group II 
by investigators. Forty‑eight patients in Group I (80.0 %) and 54 in Group II (91.5 %) rated tolerability as “good” or “very 
good”.
Conclusions: The dose escalation of a grass pollen allergoid can be accelerated with safety and tolerability profiles 
comparable to the conventional dose escalation.
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Background
Sensitization to grass pollen allergens is the most preva-
lent cause of respiratory allergy in Europe [1]. For more 
than 100  years, grass pollen allergy has been treated 
with subcutaneous immunotherapy (SCIT) applying 
increasing allergen doses to reach the efficacious main-
tenance phase. SCIT was demonstrated to be effective in 
both allergic asthma [2] and allergic rhinitis [3]. Like all 
long-term treatments [4], adherence to SCIT is affected 
by a number of factors. One of the most relevant fac-
tors is inconvenience related to commuting to receive 
the allergy injections [5–7]. Accelerated dose escalation 
allows patients to reach effective doses faster [8, 9], while 
increasing the adherence to treatment [10, 11]. The shift 
from aqueous extracts to depot preparations, adsorbed 
to aluminium hydroxide or other adjuvants, allows the 
number of injections to be reduced significantly. Clus-
ter and rush schemes were introduced with the aim of 
further accelerating the dose escalation. However, these 
schemes carry an increased risk of severe systemic reac-
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allergens (so-called high-dose hypoallergenic prepara-
tions or allergoids) achieved the combined goal of accel-
erating dose escalation and administering therapeutic 
doses with a reduced potential for side effects while 
maintaining immunogenicity [13, 14]. Grass pollen aller-
goids have been demonstrated to be effective and safe 
when seven preseasonal injections were used to reach 
the maintenance dose [15]. Accelerated dose escalation 
schemes with different allergoid preparations have also 
been demonstrated to be safe and effective in previous 
studies [17, 18]. The purpose of this trial was to evaluate 
the safety and tolerability of an accelerated dose escala-
tion scheme for a grass pollen allergoid, allowing the 
recommended maintenance dose to be reached within 
a time span of 3 weeks only. This accelerated dose esca-
lation scheme can reduce the inconvenience to patients 
and improve the attractiveness of SCIT.
Methods
This was a randomized open label phase II multicentre 
clinical trial performed in Germany. Patients were rand-
omized to 2 parallel active treatment groups in 1:1 ratio. 
Group I received an accelerated dose escalation scheme 
of 4 injections at weekly intervals, and Group II received 
the conventional dose escalation scheme with 7 weekly 
injections.
Inclusion criteria
Male and female outpatients aged 18–65 years with grass 
pollen-induced IgE-mediated seasonal allergic rhino-
conjunctivitis with or without bronchial asthma con-
firmed by a positive skin prick test (grass pollen wheal 
size ≥3 mm in diameter) and a grass pollen specific IgE 
level of ≥0.70 kU/L, were included. Patients also had to 
have their major discomfort during the grass pollen sea-
son. Diagnosed asthma, if present, had to be classified as 
“controlled” according to the GINA guidelines [19].
Test product
Allergovit® 6-grasses (Allergopharma GmbH & Co. KG, 
Reinbek, Germany), a 100 % mixture of allergens from 6 
grass pollen species (Holcus lanatus, Dactylis glomerata, 
Lolium perenne, Phleum pratense, Poa pratensis, and Fes-
tuca pratensis) chemically modified with formaldehyde to 
produce an allergoid, which is then co-precipitated with 
aluminium hydroxide, was used. Allergovit® 6-grasses is 
specified in therapeutic units per mL (TU/mL), provided 
in two strengths (A: 1000 TU/mL and B: 10,000 TU/mL).
Treatment
Patients randomized to Group I were treated for up to 
12  weeks, and patients randomized to Group  II were 
treated for up to 15  weeks. The injections of gradually 
increasing doses were administered weekly, and the doses 
were increased one step at a time, provided the previ-
ous dose had been well tolerated. In Group I, patients 
received 2 injections of strength A and 2 injections of 
strength B, with volumes of 0.2 and 0.6 mL, respectively. 
In Group II, patients received 4 injections of strength 
A with volumes of 0.1, 0.2, 0.4 and 0.8 mL, and 3 injec-
tions of strength B with volumes of 0.15, 0.3 and 0.6 mL. 
When the maximum dose had been reached, both groups 
received maintenance treatment with 2 maximum dose 
injections of 6000 TU/ml after 14 and 28 days. This dose 
corresponds to a content of 25 μg of grass group 5 aller-
gens [20]. To enable rapid intervention in case of allergic 
reactions, patients in Group I received a venous catheter 
prior to each injection remaining in place until the end of 
supervision. The minimum supervision time at the trial 
site was 120  min for Group I and 30  min for Group II. 
The 2 treatment schemes are shown in Fig. 1.
Criteria for evaluation
Adverse events (AEs) and serious adverse events (SAEs) 
were assessed by the investigator and coded using Med-
DRA version 15.0 according to primary System Organ 
Class (SOC) and Preferred Term (PT). The safety end-
points were as follows:
  • AEs considered to be related to the trial medication 
by the investigator;
  • intensity of treatment-emergent AEs (TEAEs) 
as judged by the investigator (mild  =  transient 
symptoms, no interference with the patient’s daily 
activities; moderate  =  marked symptoms, moder-
ate interference with the patient’s daily activities; 
Fig. 1 Dose escalation schemes in Group I and II. The maximal dose 
of 6000 TU was repeated after 14 and 28 days in both groups
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severe = considerable interference with the patient’s 
daily activities);
  • incidence and intensity of systemic reactions after 
injections according to a modified WAO classifica-
tion using only the symptoms (no consideration of 
epinephrine administration) documented and judged 
by the investigator [21]. The classification was super-
vised by the Data Safety Monitoring Board;
  • number, incidence, type, and intensity of local AEs 
(local reactions at the injection site >5 cm);
  • number of local reactions at the injection site ≤5 cm, 
which were not considered as AEs;
  • changes in laboratory values (haematology, clinical 
chemistry, and urinalysis) measured before and after 
the treatment phase;
  • changes in vital signs and lung function measured 
before, during, and after treatment.
  • the assessment of the overall tolerability of treat-
ment by the investigator and the patient was per-
formed using a 5-point Likert scale (1 = very bad and 
5 = very good) [22].
Statistical methods
Safety data were analysed descriptively. Due to the explor-
atory design of this study, there was no formal estima-
tion of sample size to account for type I error rate, power, 
standard deviation, and effect size. However, a sample size 
of 120 patients, 60 patients per group, was chosen, and the 
patients were randomized to the 2 treatment groups. This 
sample size was considered sufficient to guarantee a prob-
ability of 95 % that AEs with a true incidence rate of 5 % in 
one treatment group occur at least once in that treatment 
group. Thus, the sample size used in this trial was consid-
ered to allow for the observation of less frequently occur-
ring AEs and the comparison of AE profiles and changes 
in vital signs and laboratory values.
Ethical conduct of the trial
Patients willing to participate in the trial were asked to 
provide written informed consent after being given suf-
ficient time to consider participation and the opportu-
nity to ask any questions they had regarding the study. 
The informed consent form was signed and personally 
dated by both the patient and the investigator. The trial 
was conducted in accordance with the trial protocol, the 
International Conference on Harmonization guideline 
for Good Clinical Practice, applicable local regulations 
and the Declaration of Helsinki.
Results
Study population
For this study, 186 patients (All-Patients Set—APS) 
were screened and 123 were randomized. One patient 
withdrew his consent prior to the first drug adminis-
tration. One-hundred twenty-two patients, 61 in each 
treatment group, received at least one dose of trial medi-
cation (Safety Set—SAF). In the Safety Set 7 patients 
left the study prematurely, including 5 Group  I patients 
and 2 Group  II patients. The reasons for premature 
trial termination in Group I were occurrence of AEs (3 
patients) and other reasons (2 patients). The 2 patients 
in Group II terminated the study due to other reasons 
(Fig.  2). Both treatment groups were well-balanced in 
their demographic and other baseline characteristics. 
The mean treatment durations were 68.8  ±  18.7  days 
and 92.3 ± 12.4 days in Groups I and II, respectively. In 
Groups I and II, 75.4 and 88.5 % of patients reached the 
maintenance dose without back dosing, respectively.
Adverse events
Sixteen non-treatment-emergent AEs in 15 patients were 
reported. One non-treatment-emergent adverse event 
(phobia) in 1 patient in Group I was related to the trial 
procedure. This patient withdrew from the study before 
receiving any injections. During the entire trial duration, 
which included the dose escalation phase and 2 mainte-
nance dose injections, 78 (63.9 %) patients reported 197 
TEAEs. The occurrence of TEAEs was similar between 
the 2 groups. The majority (53, 43.4  %) of patients only 
reported mild TEAEs. One serious and severe TEAE 
(peritonsillar abscess), which was not related to the 
trial medication or procedure, was reported during the 
dose escalation phase in a patient in Group II receiv-
ing 0.1 mL of strength A. The most frequently reported 
TEAEs belonged to the SOC of “infections and infesta-
tions”. Slightly more patients in Group II reported these 
types of AEs (Group I: 36.1 %, Group II: 45.9 %). Eighty-
one TEAEs reported by 37 (30.3 %) patients were related 
to the trial medication. In Group I, 22 patients (36.1 %) 
reported treatment-related TEAEs, compared to 15 
(24.6 %) patients in Group II. Most events reported were 
mild in intensity (Table 1). For TEAEs related to the trial 
medication, the most frequent reported SOC in both 
Group I (29.5  % of patients) and Group II (19.7  % of 
patients) was “general disorders and administration site 
conditions” (PTs: injection site swelling, injection site 
erythema, injection site pruritus, injection site warmth, 
injection site discomfort, injection site reaction, and 
injection site urticaria).
Local reactions
Thirty-eight local reactions (>5 cm) related to treatment 
were reported in 18 (29.5 %) patients in Group I and 27 
local reactions were reported in 11 (18.0  %) patients in 
Group II (95 %-CI for risk difference: −3.9 % to 26.6 %). 
The majority of local reactions (20 events in 11 patients 
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[18.0  %] in Group I and 17 events in 6 patients [9.8  %] 
in Group II) were observed under strength A treatment. 
During the entire study, the mean maximal diameter of 
local reactions per visit was highly comparable between 
both treatment groups, with an average maximal size of 
2.1 ± 1.6 cm in Group I and 2.0 ± 1.7 cm in Group II.
Systemic reactions
Overall, systemic allergic reactions were more fre-
quently reported in Group I than in Group II (Group 
I: 8, 13.1 % vs Group II: 4, 6.6 % [CI for risk difference: 
−4.8–18.4 %]). Most of these reactions were WAO Grade 
1. Overall, 5 reactions were Grade 2 (3 in Group I and 2 
in Group II) and no reaction was classified as Grade 3, 4, 
or 5 (Table 2). Epinephrine was never administered.
Laboratory parameters, vital signs, and lung function
Except for 1 patient in Group II with an abnormal plate-
let count at the final visit, no clinically significant change 
from baseline for any laboratory parameter was reported. 
This change was not considered an AE or related to study 
treatment. The lung function tests and vital sign meas-
urements performed after the injections did not show 
Fig. 2 Patient flow‑chart
Table 1 Intensity of systemic and local reactions
a Each patient counted once under the highest intensity








Mild 8 (13.1 %) 2 (3.3 %)
Moderate 0 (0.0 %) 2 (3.3 %)
Severe 0 (0.0 %) 0 (0.0 %)
Injection site 
swelling
Mild 10 (16.4 %) 5 (8.2 %)
Moderate 2 (3.3 %) 1 (1.6 %)
Severe 1 (1.6 %) 0 (0.0 %)
Injection site 
erythema
Mild 10 (16.4 %) 7 (11.5 %)
Moderate 1 (1.6 %) 0 (0.0 %)
Severe 0 (0.0 %) 0 (0.0 %)
Table 2 WAO classification of  treatment-related systemic 
reactions
a Peak expiratory flow decrease without clinical symptoms




Reactions per number of injections
 Total number of injections 371 557
 Injections without reactions 362 (97.6 %) 553 (99.3 %)
 WAO Grade 1 5 (1.3 %) 2 (0.4 %)
 WAO Grade 2 3 (0.8 %) 2 (0.4 %)
 WAO Grade not classified 1 (0.3 %)a 0 (0.0 %)
Patients with systemic reactions
 Total number of patients 61 61
 Patients without reaction 52 (85.2 %) 57 (93.4 %)
 WAO Grade 1 5 (8.2 %) 2 (3.3 %)
 WAO Grade 2 3 (4.9 %) 2 (3.3 %)
 WAO Grade not classified 1 (1.6 %)a 0 (0.0 %)
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systematic changes in any parameter for any treatment 
group. Vital signs at the final visit did not show clinically 
significant changes from baseline.
Tolerability
After treatment, the overall tolerability was assessed by 
investigators and patients separately. Investigators rated 
the treatment tolerability as “good” or “very good” for 53 
(86.9  %) patients in Group I and 59 (100  %) patients in 
Group II. In Group I, 48 patients (80.0 %) and in Group 
II 54 patients (91.5 %) rated the treatment tolerability as 
“good” or “very good” (Fig. 3).
Discussion
This trial demonstrates that the dose escalation of a 
high-dose grass pollen allergoid for SCIT can be acceler-
ated to 4 injections in weekly intervals with acceptable 
safety and good tolerability profiles, overall compara-
ble to those of the conventional dose escalation scheme 
comprising 7 injections. As expected we observed an 
increase of systemic events during the accelerated dose 
escalation corresponding to the high amount of major 
allergen in the vaccine. However, type and intensity of 
AEs, drug-related AEs, and systemic reactions were 
similar between the patients receiving SCIT in the accel-
erated dose escalation and the patients treated in the 
conventional scheme. An accelerated dose escalation 
phase offers several advantages. First of all, it allows the 
patients to reach the recommended maintenance dose 
faster. Clinical benefits and immunological responses of 
SCIT have been shown to appear very shortly after the 
maintenance dose has been reached [8, 9, 11, 23, 24]. 
Accelerating the dose escalation phase also addresses the 
issue of adherence to allergen immunotherapy (AIT). It 
is known from several studies, that the efficacy of SCIT, 
as with all long-term treatments, can be impaired by 
poor compliance, even if it can be argued that it is better 
than in sublingual AIT [4–6, 25, 26]. Lack of compliance 
is a restraint against AIT [27, 28]. Interestingly, in one 
study comparing the adherence to rush and conventional 
dose escalation schemes, the majority of patients who 
terminated were found in the conventional dose escala-
tion group [11]. Accelerating the dose escalation phase 
to a duration of 3  weeks, as done in this trial, could 
reduce inconveniences and increase treatment adher-
ence. Several studies with this aim have evaluated the 
Fig. 3 Tolerability assessment by investigators and patients
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safety of accelerated dose escalation phases for aeroaller-
gen extracts, either by reducing the number of injections 
or by adopting rush or cluster schemes. Rush schemes 
seem to carry a higher risk of systemic reactions; in 
comparison, cluster schemes are characterized by a bet-
ter benefit/risk ratio [8–10, 24]. In this study, we were 
able to show that an acceleration of the dose escalation 
was safe and well-tolerated, though we saw a higher fre-
quency in local reactions and mild systemic events.
The majority of patients and investigators rated the 
accelerated scheme tolerability as “good” or “very good”. 
Some differences in tolerability can also be explained by 
the open label study design: for safety reasons patients in 
Group I had to wait 120 min after the injection, and the 
Federal Institute for Vaccines and Biomedicines (Paul-
Ehrlich-Institute) requested that all patients in the accel-
erated dose escalation group were asked to carry a single 
use indwelling catheter with them during each injection. 
Therefore, patients in the accelerated dose escalation 
group may have experienced more psychological stress 
prior to and after allergen injection than patients treated 
with the conventional scheme. Nevertheless, the tolera-
bility rating by the patients was positive in both schemes. 
The difference in the tolerability rating by the investiga-
tors may also be explained by the open study design and 
the additional efforts imposed on the investigators.
Meanwhile, regulatory authorities in Germany have 
granted marketing authorization for the accelerated updos-
ing scheme of the investigated study drug. Efficacy of the 
study drug has been shown in double-blind, placebo con-
trolled trials [15, 16], where in the latter trial a cumulative 
dose of 12,000 BU per protocol resulted in clinical benefit 
after one pre-seasonal updosing course. Patients during this 
study received per protocol a cumulative dose of 20.800 TU 
(group I) and 24.000 TU (group II), including 2 additional 
maintenance doses after updosing, respectively.
The efficacy of AIT is known to be dose-dependent at 
maintenance-dose level [29]. Examination of modified 
updosing schemes did not alter the induction of systemic 
IgG4 responses in a recent study [30].
Conclusions
In conclusion, the dose escalation scheme of a grass pol-
len allergoid can be accelerated from the conventional 
7–4 injections in weekly intervals with comparable safety 
and tolerability profiles. This accelerated dose escalation 
is expected to attract more patients to undergo SCIT and 
benefit from its clinical and immunological effects.
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